Please assess the completion status of the following clinical trial:

Trial Title: Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~1. Histologically confirmed CD20 positive Diffuse Large B-cell Lymphoma (DLBCL)~2. Advanced stage: stage III, IV and/or bulky disease (largest diameter ≥ 10.0 cm) regardless of stage~3. Previously untreated.~4. Performance status: ECOG 0-2.~5. Age ≥ 18~6. At least one or more bidimensionally measurable lesion(s)~   * ≥ 2 cm by conventional CT~  * ≥ 1 cm by spiral CT~  * skin lesion (photographs should be taken) ≥ 2 cm~  * measurable lesion by physical examination ≥ 2 cm~7. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormalities~8. Adequate renal function: serum creatinine level \< 2 mg/dL (177 μmol/L)~9. Adequate liver functions:~   * Transaminase (AST/ALT) \< 3 X upper normal value (or \< 5 x ULN in the presence of DLBCL involvement of the liver)~  * Bilirubin \< 2 X upper normal value (or \< 5 x ULN in the presence of DLBCL involvement of the liver)~10. Adequate hematological function: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow involvement by lymphoma~11. Life expectancy ≥ 6 months~12. A negative serum or urine pregnancy test prior to treatment must be available both for pre menopausal women and for women who are \< 1 years after the onset of menopause.~13. Informed consent~Exclusion criteria~1. Other subtypes NHL than DLBCL~2. Patients who transformed follicular lymphoma or other indolent lymphoma~3. Primary Central Nervous System (CNS) DLBCL;~4. CNS involvement by lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks) in case of clinical suspicion of CNS involvement by lymphoma. Patients who have only had prophylactic intrathecal chemotherapy against CNS disease are eligible.~5. Patients with a known history of HIV seropositivity or HCV (+). Patients who have HBV (+) are eligible. However, primary prophylaxis using antiviral agents (i.e. lamivudine) is recommended for HBV carrier to prevent HBV reactivation during whole treatment period.~6. Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri~7. Pregnant or lactating women, women of childbearing potential not employing adequate contraception~8. Other serious illness or medical conditions~   * Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry~  * History of significant neurological or psychiatric disorders including dementia or seizures~  * Active uncontrolled infection (viral, bacterial or fungal infection)~  * Other serious medical illnesses~9. Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies)~10. Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).